id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-N-1636-0002,FDA,FDA-2024-N-1636,Issuance of Priority Review Voucher; Rare Pediatric Disease Product; KEBILIDI (eladocagene exuparvovectneq),Notice,Announcement,2024-12-02T05:00:00Z,2024,12,2024-12-02T05:00:00Z,,2024-12-02T15:11:50Z,2024-28206,0,0,0900006486843d8e
FDA-2024-N-1636-0001,FDA,FDA-2024-N-1636,Issuance of Priority Review Voucher; Rare Pediatric Disease Product; LENMELDY (Atidarsagene Autotemcel),Notice,Announcement,2024-04-18T04:00:00Z,2024,4,2024-04-18T04:00:00Z,,2024-04-19T12:40:33Z,2024-08276,0,0,09000064864de1e3